CD274 and non-small cell lung carcinoma: In advanced non‐small‐cell lung cancer (NSCLC) cases—either metastatic or locally progressive—without targetable driver alterations, PD‐(L)1 axis inhibition has emerged as the preferred first‐line therapy, offering substantial survival advantages compared to historical standards [2, 3, 4, 5, 6, 7, 8].